IQVIA (IQV) is sliding in Friday trading (March 27, 2026), with the move largely tied to continued fallout from the company’s 2026 profit outlook and the market’s ongoing de-risking of the contract research organization (CRO) group. The stock’s recent weakness has been framed around IQVIA’s 2026 adjusted EPS guidance range of $12.55 to $12.85, which came in below prior expectations and has kept investors focused on visibility and margin durability rather than the prior-quarter beat. (tipranks.com)

The key issue for investors has been the 2026 earnings outlook versus consensus, with higher net interest expense flagged as a meaningful headwind following financing activities. With rates and credit costs still pressuring leveraged business models, the market reaction has been to compress valuation multiples rather than give full credit for bookings/backlog messaging, leaving IQVIA exposed to incremental risk-off days even without a new company announcement. (trefis.com)

Several firms have trimmed targets in the wake of the outlook reset, which has helped sustain negative momentum on down-market sessions. In early February, Evercore ISI reduced its price target while keeping an Outperform rating, pointing to concerns around AI-related shifts and the need for clearer upside drivers. (investing.com)

The next major catalyst is IQVIA’s upcoming quarterly report (commonly tracked as late April 2026), when investors will look for updated pacing on R&D Solutions demand, net new business trends, and any changes to the 2026 EPS bridge—especially interest expense and operating leverage. Until then, the stock may trade more like a sentiment gauge for CRO spending and financing-cost pressure than a pure company-specific story. (explore.nemo.money)